Figure 7. Human umbilical vein endothelial cells (HUVECs) were subjected to oxygen-glucose deprivation and reoxygenation (OGD/R) for 4 h prior to engeletin treatment for 24 h, after which western blotting was used to assess protein levels. Cells were treated with axitinib (1 μM, VEGFR-inhibitor) and engeletin (400 nM) for 24 h and then VEGF, Vash-1, and Vash-2 levels were assessed. Data are reported as means±SD (n=3). *P<0.05, **P<0.01 vs OGD/R group; ^#P<0.05 vs control group. ^△P<0.05, ^△△P<0.01 vs engeletin group (ANOVA with Tukey's test). Vash: vasohibin.